Biogen Inc.

Chamath support ×2 ▼ on 📈 Alzheimer's amyloid hypothesis was built on fraud - the anti-amyloid franchise busts E89 · 2022-07-29 ▶ 1:07:52

No, what I'm saying is the NIH budget per year for Alzheimer's and dementia is 1.9 billion. Half of it, if you look at the tags, if you just search the tags, half the money has gone into Alzheimer's disease, amyloid beta.

Friedberg support ×3 ▼ on 📈 Alzheimer's amyloid hypothesis was built on fraud - the anti-amyloid franchise busts E89 · 2022-07-29 ▶ 1:08:55

And now the drug is in the market. Biogen gets approval and people start taking it. And we're seeing the data. It doesn't work. And no one wants to use it. So the market has collapsed and you kind of go back to the origin.

Friedberg reversal ×2 ▲ on 📈 FDA's loosened approval bar creates markets — capital floods the biotech complex E80 · 2022-05-13 ▶ 29:08

roughly one third of public biotech stocks are trading below cash. ... But because the capital markets are gone now for them, or the assumption is, hey, there's not going to be any capital left

Friedberg support ×2 ▲ on 📈 FDA's loosened approval bar creates markets — capital floods the biotech complex E59 · 2021-12-17 ▶ 1:09:02

they really kind of struggled for years to find the right footing of what's the right business model and the right product and the FDA kind of struggled with approving this stuff. And then boom, COVID hit. ... I think there's now a few, a handful of these RNA interference products that have been approved by the FDA. And we're now starting to see many more of these cancer and immunotherapy drugs start to get approved as RNA therapies.

Sacks support ×2 ▲ on 📈 FDA's loosened approval bar creates markets — capital floods the biotech complex E35 · 2021-06-13 ▶ 17:08

But going to the sort of larger issue of FDA approval, I would make it a little bit easier to get drugs approved. I mean, look, I think that double-blind test is the gold standard. If the drug clearly doesn't work, you don't approve it. But this is a case where the evidence is a little bit inconclusive.

Friedberg support ×2 ▲ on 📈 FDA's loosened approval bar creates markets — capital floods the biotech complex E35 · 2021-06-13 ▶ 23:27

Companies are going to rush in, they're going to try and get 10 things approved. Everyone's going to be taking an Alzheimer's drug in a couple of years because there's going to be so many available on the market. And none of them may actually be curing Alzheimer's.

Chamath support ×3 ▲ on 📈 FDA's loosened approval bar creates markets — capital floods the biotech complex E35 · 2021-06-13 ▶ 20:55

they applied an extremely aggressive free market approach to a market that has been completely bereft of solutions. ... And so if you can create a hundred billion dollar market overnight, I think it stands to reason that a lot of people will look at the increase in Biogen's market cap and the profits that Biogen can make over the next 10 or 15 years and say, I will attack that and do that cheaper, faster, better. It happens in every other market.